A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes

Biochemical Pharmacology

Volumn 79, Issue 10, 2010, Pages 1398-1409

  Zhang, Xiaolei ^a   Yue, Peibin ^a   Fletcher, Steven ^b   Zhao, Wei ^a   Gunning, Patrick T ^b   Turkson, James ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antitumor cell effects; Antitumor effects; S3I 201; S3I 201.1066; Small molecule inhibitor; Stat3

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTYROSINE; PROTEIN SH2; PROTEIN TYROSINE KINASE; S 31 2011066; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CANCER CELL; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DNA BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; EMBRYO; ENZYME ACTIVATION; FEMALE; FIBROBLAST; GENE CONTROL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

AMINOSALICYLIC ACIDS; ANIMALS; BENZENESULFONATES; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC HOMOLOGY DOMAINS; STAT3 TRANSCRIPTION FACTOR; SURFACE PLASMON RESONANCE; TRANSCRIPTIONAL ACTIVATION;

EID: 77649178678     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.01.001     Document Type: Article

References (54)

1. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res 2 (2000) 86-90
2. Darnell Jr. J.E. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2 (2002) 740-749
3. Schröder M., Kroeger K., Volk H.D., Eidne K.A., and Grütz G. Preassociation of nonactivated STAT3 molecules demonstrated in living cells using bioluminescence resonance energy transfer: a new model of STAT activation?. J Leukoc Biol 75 (2004) 792-797
4. Sehgal P.B. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol 19 (2008) 329-340
5. Bromberg J., and Darnell Jr. J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 (2000) 2468-2473
6. Bowman T., Garcia R., Turkson J., and Jove R. STATs in oncogenesis. Oncogene 19 (2000) 2474-2488
7. Turkson J., and Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19 (2000) 6613-6626
8. Buettner R., Mora L.B., and Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8 (2002) 945-954
9. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4 (2004) 97-105
10. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8 (2004) 409-422
11. Darnell J.E. Validating Stat3 in cancer therapy. Nat Med 11 (2005) 595-596
12. Kortylewski M., and Yu H. Stat3 as a potential target for cancer immunotherapy. J Immunother 30 (2007) 131-139
13. Kortylewski M., and Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20 (2008) 228-233
14. Shuai K., Horvath C.M., Huang L.H., Qureshi S.A., Cowburn D., and Darnell Jr. J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76 (1994) 821-828
15. Turkson J., Ryan D., Kim J.S., Zhang Y., Chen Z., Haura E., et al. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J Biol Chem 276 (2001) 45443-45455
16. Turkson J., Kim J.S., Zhang S., Yuan J., Huang M., Glenn M., et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3 (2004) 261-269
17. Siddiquee K., Glenn M., Gunning P., Katt W.P., Zhang S., Schroeck C., et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2 (2007) 787-798
18. Siddiquee K., Zhang S., Guida W.C., Blaskovich M.A., Greedy B., Lawrence H., et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. 1. Proc Natl Acad Sci U S A 104 (2007) 7391-7396
19. Song H., Wang R., Wang S., and Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 102 (2005) 4700-4705
20. Yue P., and Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin Investig Drugs 18 (2009) 45-56
21. Coleman D.R.I., Ren Z., Mandal P.K., Cameron A.G., Dyer G.A., Muranjan S., et al. Investigation of the binding determinants of phosphopeptides targeted to the Src Homology. 2. Domain of the signal transducer and activator of transcription. 3. Development of a high-affinity peptide inhibitor. J Med Chem 48 (2005) 6661-6670
22. Ren Z., Cabell L.A., Schaefer T.S., and McMurray J.S. Identification of a high-affinity phosphopeptide inhibitor of stat3. Bioorg Med Chem Lett 13 (2003) 633-636
23. Schust J., and Berg T. A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. Anal Biochem 330 (2004) 114-118
24. Gunning P.T., Glenn M.P., Siddiquee K.A., Katt W.P., Masson E., Sebti S.M., et al. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem 9 (2008) 2800-2803
25. Fletcher S., Turkson J., and Gunning P.T. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 3 (2008) 1159-1168
26. Becker S., Groner B., and Muller C.W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394 (1998) 145-151
27. Johnson P.J., Coussens P.M., Danko A.V., and Shalloway D. Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells. Mol Cell Biol 5 (1985) 1073-1083
28. Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269 (1995) 81-83
29. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20 (2001) 2499-2513
30. Ouyang H., Mou L.J., Luk C., Liu N., Karaskova J., Squire J., et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157 (2000) 1623-1631
31. Maritano D., Sugrue M.L., Tininini S., Dewilde S., Strobl B., Fu X., et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol 5 (2004) 401-409
32. Turkson J., Bowman T., Adnane J., Zhang Y., Djeu J.Y., et al. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 19 (1999) 7519-7528
33. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R.P., and Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18 (1998) 2545-2552
34. Wagner M., Kleeff J., Friess H., Buchler M.W., and Korc M. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19 (1999) 370-376
35. Gouilleux F., Moritz D., Humar M., Moriggl R., Berchtold S., and Groner B. Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor. Endocrinology 136 (1995) 5700-5708
36. Seidel H.M., Milocco L.H., Lamb P., Darnell Jr. J.E., Stein R.B., and Rosen J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci U S A 92 (1995) 3041-3045
37. Turkson J., Zhang S., Mora L.B., Burns A., Sebti S., and Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 280 (2005) 32979-32988
38. Zhang Y., Turkson J., Carter-Su C., Smithgall T., Levitzki A., Kraker A., et al. Activation of Stat3 in v-Src transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 275 (2000) 24935-24944
39. Zhao S., Venkatasubbarao K., Lazor J.W., Sperry J., Jin C., Cao L., et al. Inhibition of STAT3Tyr705 phosphorylation by Smad4 suppresses transforming growth factor β-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 68 (2008) 4221-4228
40. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267 (1997) 727-748
41. Fletcher S., Jardeephi S., Zhang X., Yue P., Page B.D., Sharmeen S., et al. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated. Salicylic acid-based small molecules: potent in vitro and tumour cell activities. ChemBioChem 10 (2009) 1959-1964
42. Siddiquee K.A.Z. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18 (2008) 254-267
43. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23 (2004) 3550-3560
44. Huang C., Cao J., Huang K.J., Zhang F., Jiang T., Zhu L., et al. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci 97 (2006) 1417-1423
45. Bhasin D., Cisek K., Pandharkar T., Regan N., Li C., Pandit B., et al. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett 18 (2008) 391-395
46. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
47. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62 (2002) 6659-6666
48. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008
49. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22 (2003) 319-329
50. Fuh B., Sobo M., Cen L., Josiah D., Hutzen B., Cisek K., et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer 100 (2009) 106-112
51. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., and Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63 (2003) 1270-1279
52. Sun J., Blaskovich M.A., Jove R., Livingston S.K., Coppola D., and Sebti S.M. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24 (2005) 3236-3245
53. Real P.J., Sierra A., De Juan A., Segovia J.C., Lopez-Vega J.M., and Fernandez-Luna J.L. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21 (2002) 7611-7618
54. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12 (2006) 11-19